Results

1–8 of 8 results for Switch

Aflibercept Monotherapy vs Initial Bevacizumab Followed by Aflibercept if Needed for Treatment of Center-Involved Diabetic Macular Edema
Chirag D. Jhaveri, MD, FASRS
Annual Meeting Talks
2022
Treatment Switch From Aflibercept to Ranibizumab Pre-filled Syringe in Canadian DME Patients in a Real-World Setting: The PRECISE Study
Michel R Giunta, MD
On Demand Cases, Courses, and Papers
2021
Early Switch to the Dexamethasone Implant After Sub-Optimal Response to Anti-VEGF Therapy for Diabetic Macular Edema
Shawn Kavoussi, MD
Annual Meeting Talks
2021
Treatment Switch From Aflibercept to Ranibizumab Pre-filled Syringe in Canadian nAMD and DME Patients in a Real-World Setting: The PRECISE Study
Ananda Kalevar, MD, FRCS(C), DABO
On Demand Cases, Courses, and Papers
2020
Switching to Combination OPT-302 With Aflibercept From Prior Anti-VEGF-A Monotherapy in Eyes With Persistent Diabetic Macula Edema (DME)
David S. Boyer, MD
Annual Meeting Talks
2020
Clinical Outcomes of Eyes with Diabetic Macular Edema Switched from Aflibercept to Ranibizumab Therapy
Michael A Klufas, MD
On Demand Cases, Courses, and Papers
2019
Anti-VEGF treatment switch in DME and nAMD: a comparison of aflibercept versus ranibizumab after a single-dose switch
Estephania Feria, MD
On Demand Cases, Courses, and Papers
2019
Anti-VEGF treatment switch in DME and nAMD: a comparison of aflibercept versus ranibizumab after a single-dose switch
Estephania Feria, MD
On Demand Cases, Courses, and Papers
2019